论文部分内容阅读
目的探讨IB期非小细胞肺癌(NSCLC)组织中runt相关转录因子2(Runx2)与埃兹蛋白(Ezrin)表达与临床生物学行为及术后复发转移的关系。方法收集IB期NSCLC手术切除石蜡标本40例,根据术后3年内有无复发转移分为复发/转移组和对照组,每组20例。应用免疫组化方法检测石蜡组织中Runx2与Ezrin的表达,并应用Kaplan-Meier法分析其表达与IB期NSCLC患者无病生存率之间的关系。结果复发/转移组Runx2、Ezrin的阳性表达率明显高于对照组(P=0.004,P=0.011)。Runx2、Ezrin的阳性表达在低分化的IB期NSCLC组织中较中、高分化组织中高(P=0.016,P=0.009);Runx2与Ezrin的表达呈显著正相关(r=0.646,P=0.001)。Runx2阳性和阴性表达患者术后3年无病生存率分别为30.4%、76.5%,差异有统计学意义(P=0.010);Ezrin阳性和阴性表达患者术后3年无病生存率分别为31.8%、72.2%,差异有统计学意义(P=0.011)。结论 Runx2及Ezrin表达与IB期NSCLC术后复发/转移密切相关,可以作为评估IB期NSCLC患者预后的指标。
Objective To investigate the relationship between Runt-related transcription factor 2 (Runx2) and Ezrin expression and clinical biological behavior and postoperative recurrence and metastasis in stage IB non-small cell lung cancer (NSCLC). Methods Forty cases of paraffin-embedded specimens of stage IB NSCLC were collected and divided into recurrence / metastasis group and control group according to the presence or absence of recurrence within 3 years after operation. Immunohistochemistry was used to detect the expression of Runx2 and Ezrin in paraffin tissue. Kaplan-Meier method was used to analyze the relationship between Runx2 expression and disease-free survival in patients with stage IB NSCLC. Results The positive rate of Runx2 and Ezrin in the recurrence / metastasis group was significantly higher than that in the control group (P = 0.004, P = 0.011). The positive expressions of Runx2 and Ezrin were significantly correlated with the expression of Ezrin in poorly differentiated stage IB NSCLC tissues (P = 0.016, P = 0.009), and positively correlated with Ezrin (r = 0.646, P = 0.001) . The 3-year disease-free survival rates of patients with Runx2 positive and negative expression were 30.4% and 76.5%, respectively, with significant difference (P = 0.010). The 3-year disease-free survival rates of patients with positive and negative Runx2 expression were 31.8 %, 72.2%, the difference was statistically significant (P = 0.011). Conclusion The expressions of Runx2 and Ezrin are closely related to the postoperative recurrence / metastasis in stage IB NSCLC and may be used as an index to evaluate the prognosis of patients with stage IB NSCLC.